Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features - 08/09/20
Abstract |
Antineoplastic agents that use the immune system have revolutionized cancer treatment. Specifically, implementation of immune checkpoint inhibitors, monoclonal antibodies that block cytotoxic T-lymphocyte–associated antigen-4, programmed cell death protein 1, or programmed cell death ligand 1 show improved and sustained responses in patients with cancer. However, these agents are associated with a plethora of adverse events, many manifesting in the skin. As the clinical application of cancer immunotherapies expands, understanding the clinical and histopathologic features of associated cutaneous toxicities becomes increasingly important to dermatologists, oncologists, and pathologists to ensure timely diagnosis and appropriate care. This review discusses cutaneous reactions to immune checkpoint inhibitors, focusing on histopathologic features.
Le texte complet de cet article est disponible en PDF.Key words : adverse event, atezolizumab, avelumab, bullous pemphigoid, checkpoint inhibitor, CTLA-4, cutaneous, durvalumab, immunotherapy, ipilimumab, lichenoid dermatitis, nivolumab, PD1, PD-L1, pembrolizumab, rash, skin, toxicity
Abbreviations used : AA, AE, BP, CTLA-4, CXCL, PD-1, PD-L1
Plan
| Funding sources: The research reported in this publication was supported in part by the Dermatology Foundation, through Dermatopathology Career Development Award (Dr Kiuru); National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number K23AR074530 (Dr Kiuru); Berg, Lutris, Paxman, Novocure, US Biotest, and Veloce (Dr Lacouture); and the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30-CA0-08748 and National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number U01AR077511 (Dr Lacouture). |
|
| Conflicts of interest: Dr Lacouture has a consultant/speaking role with Legacy Healthcare Services, Adgero, Amryt, Celldex, Debiopharm, Galderma, Johnson and Johnson, Novocure, Lindi, Merck Sharp and Dohme, BMS, Helsinn, Janssen, Menlo, Novartis, F. Hoffmann-La Roche AG, AbbVie Inc, Boehringer Ingelheim, Allergan, Amgen, E.R. Squibb & Sons LLC, EMD Serono, AstraZeneca, Genentech, LEO Pharma, Seattle Genetics, Bayer, Lutris, Pierre Fabre, Paxman Coolers, Adjucare, Dignitana, Biotechspert, Teva, Parexel, OnQuality, Novartis, Harborside, Wiley, Azitra, NCODA, and Takeda Millenium. Drs Ellis, Vierra, Millsop, and Kiuru have no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
Vol 83 - N° 4
P. 1130-1143 - octobre 2020 Retour au numéro
Article précédent
- The spectrum of COVID-19–associated dermatologic manifestations: An international registry of 716 patients from 31 countries
- Esther E. Freeman, Devon E. McMahon, Jules B. Lipoff, Misha Rosenbach, Carrie Kovarik, Seemal R. Desai, Joanna Harp, Junko Takeshita, Lars E. French, Henry W. Lim, Bruce H. Thiers, George J. Hruza, Lindy P. Fox
- Nanoparticles in dermatologic surgery
- Peter W. Hashim, John K. Nia, George Han, Desiree Ratner
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?